APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nivolumab Market Analysis and Forecast 2026-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchNivolumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Nivolumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nivolumab market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Nivolumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nivolumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nivolumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nivolumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Nivolumab include Ono Pharmaceutical and Bristol-Myers Squibb etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Nivolumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nivolumab, also provides the sales of main regions and countries. Of the upcoming market potential for Nivolumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nivolumab sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nivolumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Nivolumab sales, projected growth trends, production technology, application and end-user industry.

Nivolumab Segment by Company

Ono Pharmaceutical

Bristol-Myers Squibb

Nivolumab Segment by Type

Injection 4mL

Injection 10mL

Nivolumab Segment by Application

Metastatic Squamous NSCLC

Metastatic Melanoma

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Unresectable Melanoma

Others

Nivolumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Nivolumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Nivolumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nivolumab sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nivolumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection 4mL Major Manufacturers Table 3. Injection 10mL Major Manufacturers Table 4. Global Nivolumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Metastatic Squamous NSCLC Major Manufacturers Table 6. Metastatic Melanoma Major Manufacturers Table 7. Renal Cell Carcinoma Major Manufacturers Table 8. Classical Hodgkin Lymphoma Major Manufacturers Table 9. Unresectable Melanoma Major Manufacturers Table 10. Others Major Manufacturers Table 11. Nivolumab Industry Trends Table 12. Nivolumab Industry Drivers Table 13. Nivolumab Industry Opportunities and Challenges Table 14. Nivolumab Industry Restraints Table 15. Global Nivolumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Nivolumab Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Nivolumab Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Nivolumab Revenue Market Share by Region (2021-2026) Table 19. Global Nivolumab Revenue Market Share by Region (2027-2032) Table 20. Global Nivolumab Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global Nivolumab Sales by Region (2021-2026) & (k units) Table 22. Global Nivolumab Sales by Region (2027-2032) & (k units) Table 23. Global Nivolumab Sales Market Share by Region (2021-2026) Table 24. Global Nivolumab Sales Market Share by Region (2027-2032) Table 25. Global Nivolumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Nivolumab Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Nivolumab Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Nivolumab Sales Market Share by Manufacturers (2021-2026) Table 29. Global Nivolumab Sales Price (US$/unit) of Manufacturers (2021-2026) Table 30. Global Nivolumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Nivolumab Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Nivolumab Manufacturers, Product Type & Application Table 33. Global Nivolumab Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Nivolumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Nivolumab Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Nivolumab Revenue Market Share by Type (2021-2026) Table 40. Global Nivolumab Revenue Market Share by Type (2027-2032) Table 41. Global Nivolumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global Nivolumab Sales by Type (2021-2026) & (k units) Table 43. Global Nivolumab Sales by Type (2027-2032) & (k units) Table 44. Global Nivolumab Sales Market Share by Type (2021-2026) Table 45. Global Nivolumab Sales Market Share by Type (2027-2032) Table 46. Global Nivolumab Price by Type (2021-2026) & (US$/unit) Table 47. Global Nivolumab Price by Type (2027-2032) & (US$/unit) Table 48. Global Nivolumab Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Nivolumab Revenue Market Share by Application (2021-2026) Table 52. Global Nivolumab Revenue Market Share by Application (2027-2032) Table 53. Global Nivolumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global Nivolumab Sales by Application (2021-2026) & (k units) Table 55. Global Nivolumab Sales by Application (2027-2032) & (k units) Table 56. Global Nivolumab Sales Market Share by Application (2021-2026) Table 57. Global Nivolumab Sales Market Share by Application (2027-2032) Table 58. Global Nivolumab Price by Application (2021-2026) & (US$/unit) Table 59. Global Nivolumab Price by Application (2027-2032) & (US$/unit) Table 60. Ono Pharmaceutical Company Information Table 61. Ono Pharmaceutical Business Overview Table 62. Ono Pharmaceutical Nivolumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 63. Ono Pharmaceutical Nivolumab Product Portfolio Table 64. Ono Pharmaceutical Recent Development Table 65. Bristol-Myers Squibb Company Information Table 66. Bristol-Myers Squibb Business Overview Table 67. Bristol-Myers Squibb Nivolumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Bristol-Myers Squibb Nivolumab Product Portfolio Table 69. Bristol-Myers Squibb Recent Development Table 70. North America Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 71. North America Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 72. North America Nivolumab Sales by Type (2021-2026) & (k units) Table 73. North America Nivolumab Sales by Type (2027-2032) & (k units) Table 74. North America Nivolumab Sales Price by Type (2021-2026) & (US$/unit) Table 75. North America Nivolumab Sales Price by Type (2027-2032) & (US$/unit) Table 76. North America Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 77. North America Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 78. North America Nivolumab Sales by Application (2021-2026) & (k units) Table 79. North America Nivolumab Sales by Application (2027-2032) & (k units) Table 80. North America Nivolumab Sales Price by Application (2021-2026) & (US$/unit) Table 81. North America Nivolumab Sales Price by Application (2027-2032) & (US$/unit) Table 82. North America Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. North America Nivolumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 84. North America Nivolumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 85. North America Nivolumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 86. North America Nivolumab Sales by Country (2021-2026) & (k units) Table 87. North America Nivolumab Sales by Country (2027-2032) & (k units) Table 88. North America Nivolumab Sales Price by Country (2021-2026) & (US$/unit) Table 89. North America Nivolumab Sales Price by Country (2027-2032) & (US$/unit) Table 90. United States Nivolumab Revenue (2021-2032) & (US$ Million) Table 91. Canada Nivolumab Revenue (2021-2032) & (US$ Million) Table 92. Mexico Nivolumab Revenue (2021-2032) & (US$ Million) Table 93. Europe Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Nivolumab Sales by Type (2021-2026) & (k units) Table 96. Europe Nivolumab Sales by Type (2027-2032) & (k units) Table 97. Europe Nivolumab Sales Price by Type (2021-2026) & (US$/unit) Table 98. Europe Nivolumab Sales Price by Type (2027-2032) & (US$/unit) Table 99. Europe Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Nivolumab Sales by Application (2021-2026) & (k units) Table 102. Europe Nivolumab Sales by Application (2027-2032) & (k units) Table 103. Europe Nivolumab Sales Price by Application (2021-2026) & (US$/unit) Table 104. Europe Nivolumab Sales Price by Application (2027-2032) & (US$/unit) Table 105. Europe Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Europe Nivolumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 107. Europe Nivolumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 108. Europe Nivolumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 109. Europe Nivolumab Sales by Country (2021-2026) & (k units) Table 110. Europe Nivolumab Sales by Country (2027-2032) & (k units) Table 111. Europe Nivolumab Sales Price by Country (2021-2026) & (US$/unit) Table 112. Europe Nivolumab Sales Price by Country (2027-2032) & (US$/unit) Table 113. Germany Nivolumab Revenue (2021-2032) & (US$ Million) Table 114. France Nivolumab Revenue (2021-2032) & (US$ Million) Table 115. U.K. Nivolumab Revenue (2021-2032) & (US$ Million) Table 116. Italy Nivolumab Revenue (2021-2032) & (US$ Million) Table 117. Russia Nivolumab Revenue (2021-2032) & (US$ Million) Table 118. Spain Nivolumab Revenue (2021-2032) & (US$ Million) Table 119. Netherlands Nivolumab Revenue (2021-2032) & (US$ Million) Table 120. Switzerland Nivolumab Revenue (2021-2032) & (US$ Million) Table 121. Sweden Nivolumab Revenue (2021-2032) & (US$ Million) Table 122. Poland Nivolumab Revenue (2021-2032) & (US$ Million) Table 123. China Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 124. China Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 125. China Nivolumab Sales by Type (2021-2026) & (k units) Table 126. China Nivolumab Sales by Type (2027-2032) & (k units) Table 127. China Nivolumab Sales Price by Type (2021-2026) & (US$/unit) Table 128. China Nivolumab Sales Price by Type (2027-2032) & (US$/unit) Table 129. China Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 130. China Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 131. China Nivolumab Sales by Application (2021-2026) & (k units) Table 132. China Nivolumab Sales by Application (2027-2032) & (k units) Table 133. China Nivolumab Sales Price by Application (2021-2026) & (US$/unit) Table 134. China Nivolumab Sales Price by Application (2027-2032) & (US$/unit) Table 135. Asia Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 136. Asia Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 137. Asia Nivolumab Sales by Type (2021-2026) & (k units) Table 138. Asia Nivolumab Sales by Type (2027-2032) & (k units) Table 139. Asia Nivolumab Sales Price by Type (2021-2026) & (US$/unit) Table 140. Asia Nivolumab Sales Price by Type (2027-2032) & (US$/unit) Table 141. Asia Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 142. Asia Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Nivolumab Sales by Application (2021-2026) & (k units) Table 144. Asia Nivolumab Sales by Application (2027-2032) & (k units) Table 145. Asia Nivolumab Sales Price by Application (2021-2026) & (US$/unit) Table 146. Asia Nivolumab Sales Price by Application (2027-2032) & (US$/unit) Table 147. Asia Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Asia Nivolumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 149. Asia Nivolumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 150. Asia Nivolumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 151. Asia Nivolumab Sales by Country (2021-2026) & (k units) Table 152. Asia Nivolumab Sales by Country (2027-2032) & (k units) Table 153. Asia Nivolumab Sales Price by Country (2021-2026) & (US$/unit) Table 154. Asia Nivolumab Sales Price by Country (2027-2032) & (US$/unit) Table 155. Japan Nivolumab Revenue (2021-2032) & (US$ Million) Table 156. South Korea Nivolumab Revenue (2021-2032) & (US$ Million) Table 157. India Nivolumab Revenue (2021-2032) & (US$ Million) Table 158. Australia Nivolumab Revenue (2021-2032) & (US$ Million) Table 159. Taiwan Nivolumab Revenue (2021-2032) & (US$ Million) Table 160. Southeast Asia Nivolumab Revenue (2021-2032) & (US$ Million) Table 161. SAMEA Nivolumab Revenue by Type (2021-2026) & (US$ Million) Table 162. SAMEA Nivolumab Revenue by Type (2027-2032) & (US$ Million) Table 163. SAMEA Nivolumab Sales by Type (2021-2026) & (k units) Table 164. SAMEA Nivolumab Sales by Type (2027-2032) & (k units) Table 165. SAMEA Nivolumab Sales Price by Type (2021-2026) & (US$/unit) Table 166. SAMEA Nivolumab Sales Price by Type (2027-2032) & (US$/unit) Table 167. SAMEA Nivolumab Revenue by Application (2021-2026) & (US$ Million) Table 168. SAMEA Nivolumab Revenue by Application (2027-2032) & (US$ Million) Table 169. SAMEA Nivolumab Sales by Application (2021-2026) & (k units) Table 170. SAMEA Nivolumab Sales by Application (2027-2032) & (k units) Table 171. SAMEA Nivolumab Sales Price by Application (2021-2026) & (US$/unit) Table 172. SAMEA Nivolumab Sales Price by Application (2027-2032) & (US$/unit) Table 173. SAMEA Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. SAMEA Nivolumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. SAMEA Nivolumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. SAMEA Nivolumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 177. SAMEA Nivolumab Sales by Country (2021-2026) & (k units) Table 178. SAMEA Nivolumab Sales by Country (2027-2032) & (k units) Table 179. SAMEA Nivolumab Sales Price by Country (2021-2026) & (US$/unit) Table 180. SAMEA Nivolumab Sales Price by Country (2027-2032) & (US$/unit) Table 181. Brazil Nivolumab Revenue (2021-2032) & (US$ Million) Table 182. Argentina Nivolumab Revenue (2021-2032) & (US$ Million) Table 183. Chile Nivolumab Revenue (2021-2032) & (US$ Million) Table 184. Colombia Nivolumab Revenue (2021-2032) & (US$ Million) Table 185. Peru Nivolumab Revenue (2021-2032) & (US$ Million) Table 186. Saudi Arabia Nivolumab Revenue (2021-2032) & (US$ Million) Table 187. Israel Nivolumab Revenue (2021-2032) & (US$ Million) Table 188. UAE Nivolumab Revenue (2021-2032) & (US$ Million) Table 189. Turkey Nivolumab Revenue (2021-2032) & (US$ Million) Table 190. Iran Nivolumab Revenue (2021-2032) & (US$ Million) Table 191. Egypt Nivolumab Revenue (2021-2032) & (US$ Million) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Nivolumab Distributors List Table 195. Nivolumab Customers List Table 196. Research Programs/Design for This Report Table 197. Authors List of This Report Table 198. Secondary Sources Table 199. Primary Sources List of Figures Figure 1. Nivolumab Image Figure 2. Global Nivolumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection 4mL Image Figure 5. Injection 10mL Image Figure 6. Global Nivolumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Nivolumab Market Size Share 2021 VS 2025 VS 2032 Figure 8. Metastatic Squamous NSCLC Image Figure 9. Metastatic Melanoma Image Figure 10. Renal Cell Carcinoma Image Figure 11. Classical Hodgkin Lymphoma Image Figure 12. Unresectable Melanoma Image Figure 13. Others Image Figure 14. Global Nivolumab Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Nivolumab Revenue (2021-2032) & (US$ Million) Figure 16. Global Nivolumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Nivolumab Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Nivolumab Revenue Market Share by Region (2021-2032) Figure 19. Global Nivolumab Sales (2021-2032) & (k units) Figure 20. Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global Nivolumab Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Nivolumab Sales YoY (2021-2032) & (k units) Figure 23. Europe Nivolumab Sales YoY (2021-2032) & (k units) Figure 24. China Nivolumab Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) Nivolumab Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa Nivolumab Sales YoY (2021-2032) & (k units) Figure 27. Global Nivolumab Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Nivolumab Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Nivolumab Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Nivolumab Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Nivolumab Revenue Market Share by Type (2021-2032) Figure 33. Global Nivolumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global Nivolumab Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Nivolumab Sales Market Share by Type (2021-2032) Figure 36. Global Nivolumab Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Nivolumab Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Nivolumab Revenue Market Share by Application (2021-2032) Figure 39. Global Nivolumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global Nivolumab Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Nivolumab Sales Market Share by Application (2021-2032) Figure 42. North America Nivolumab Revenue Share by Type (2021-2032) Figure 43. North America Nivolumab Sales Share by Type (2021-2032) Figure 44. North America Nivolumab Revenue Share by Application (2021-2032) Figure 45. North America Nivolumab Sales Share by Application (2021-2032) Figure 46. North America Nivolumab Revenue Share by Country (2021-2032) Figure 47. North America Nivolumab Sales Share by Country (2021-2032) Figure 48. Europe Nivolumab Revenue Share by Type (2021-2032) Figure 49. Europe Nivolumab Sales Share by Type (2021-2032) Figure 50. Europe Nivolumab Revenue Share by Application (2021-2032) Figure 51. Europe Nivolumab Sales Share by Application (2021-2032) Figure 52. Europe Nivolumab Revenue Share by Country (2021-2032) Figure 53. Europe Nivolumab Sales Share by Country (2021-2032) Figure 54. China Nivolumab Revenue Share by Type (2021-2032) Figure 55. China Nivolumab Sales Share by Type (2021-2032) Figure 56. China Nivolumab Revenue Share by Application (2021-2032) Figure 57. China Nivolumab Sales Share by Application (2021-2032) Figure 58. Asia Nivolumab Revenue Share by Type (2021-2032) Figure 59. Asia Nivolumab Sales Share by Type (2021-2032) Figure 60. Asia Nivolumab Revenue Share by Application (2021-2032) Figure 61. Asia Nivolumab Sales Share by Application (2021-2032) Figure 62. Asia Nivolumab Revenue Share by Country (2021-2032) Figure 63. Asia Nivolumab Sales Share by Country (2021-2032) Figure 64. SAMEA Nivolumab Revenue Share by Type (2021-2032) Figure 65. SAMEA Nivolumab Sales Share by Type (2021-2032) Figure 66. SAMEA Nivolumab Revenue Share by Application (2021-2032) Figure 67. SAMEA Nivolumab Sales Share by Application (2021-2032) Figure 68. SAMEA Nivolumab Revenue Share by Country (2021-2032) Figure 69. SAMEA Nivolumab Sales Share by Country (2021-2032) Figure 70. Nivolumab Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Nivolumab Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Injection 4mL
  • Injection 10mL
Applications
  • Metastatic Squamous NSCLC
  • Metastatic Melanoma
  • Renal Cell Carcinoma
  • Classical Hodgkin Lymphoma
  • Unresectable Melanoma
  • Others
Companies covered
  • Ono Pharmaceutical
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nivolumab Market by Type
  3. 1.2.1 Global Nivolumab Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection 4mL
  5. 1.2.3 Injection 10mL
  6. 1.3 Nivolumab Market by Application
  7. 1.3.1 Global Nivolumab Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Metastatic Squamous NSCLC
  9. 1.3.3 Metastatic Melanoma
  10. 1.3.4 Renal Cell Carcinoma
  11. 1.3.5 Classical Hodgkin Lymphoma
  12. 1.3.6 Unresectable Melanoma
  13. 1.3.7 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nivolumab Market Dynamics
  1. 2.1 Nivolumab Industry Trends
  2. 2.2 Nivolumab Industry Drivers
  3. 2.3 Nivolumab Industry Opportunities and Challenges
  4. 2.4 Nivolumab Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Nivolumab Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Nivolumab Revenue by Region
  3. 3.2.1 Global Nivolumab Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nivolumab Revenue by Region (2021-2026)
  5. 3.2.3 Global Nivolumab Revenue by Region (2027-2032)
  6. 3.2.4 Global Nivolumab Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Nivolumab Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Nivolumab Sales by Region
  9. 3.4.1 Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Nivolumab Sales by Region (2021-2026)
  11. 3.4.3 Global Nivolumab Sales by Region (2027-2032)
  12. 3.4.4 Global Nivolumab Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Nivolumab Revenue by Manufacturers
  2. 4.1.1 Global Nivolumab Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Nivolumab Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Nivolumab Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nivolumab Sales by Manufacturers
  6. 4.2.1 Global Nivolumab Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Nivolumab Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Nivolumab Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Nivolumab Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Nivolumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Nivolumab Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Nivolumab Manufacturers, Product Type & Application
  13. 4.7 Global Nivolumab Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Nivolumab Market CR5 and HHI
  16. 4.8.2 2025 Nivolumab Tier 1, Tier 2, and Tier 3
5 Nivolumab Market by Type
  1. 5.1 Global Nivolumab Revenue by Type
  2. 5.1.1 Global Nivolumab Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Nivolumab Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Nivolumab Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Nivolumab Sales by Type
  6. 5.2.1 Global Nivolumab Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nivolumab Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Nivolumab Sales Market Share by Type (2021-2032)
  9. 5.3 Global Nivolumab Price by Type
6 Nivolumab Market by Application
  1. 6.1 Global Nivolumab Revenue by Application
  2. 6.1.1 Global Nivolumab Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Nivolumab Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Nivolumab Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Nivolumab Sales by Application
  6. 6.2.1 Global Nivolumab Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Nivolumab Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Nivolumab Sales Market Share by Application (2021-2032)
  9. 6.3 Global Nivolumab Price by Application
7 Company Profiles
  1. 7.1 Ono Pharmaceutical
  2. 7.1.1 Ono Pharmaceutical Company Information
  3. 7.1.2 Ono Pharmaceutical Business Overview
  4. 7.1.3 Ono Pharmaceutical Nivolumab Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Ono Pharmaceutical Nivolumab Product Portfolio
  6. 7.1.5 Ono Pharmaceutical Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb Nivolumab Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb Nivolumab Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Nivolumab Market Size by Type
  2. 8.1.1 North America Nivolumab Revenue by Type (2021-2032)
  3. 8.1.2 North America Nivolumab Sales by Type (2021-2032)
  4. 8.1.3 North America Nivolumab Price by Type (2021-2032)
  5. 8.2 North America Nivolumab Market Size by Application
  6. 8.2.1 North America Nivolumab Revenue by Application (2021-2032)
  7. 8.2.2 North America Nivolumab Sales by Application (2021-2032)
  8. 8.2.3 North America Nivolumab Price by Application (2021-2032)
  9. 8.3 North America Nivolumab Market Size by Country
  10. 8.3.1 North America Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Nivolumab Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Nivolumab Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Nivolumab Market Size by Type
  2. 9.1.1 Europe Nivolumab Revenue by Type (2021-2032)
  3. 9.1.2 Europe Nivolumab Sales by Type (2021-2032)
  4. 9.1.3 Europe Nivolumab Price by Type (2021-2032)
  5. 9.2 Europe Nivolumab Market Size by Application
  6. 9.2.1 Europe Nivolumab Revenue by Application (2021-2032)
  7. 9.2.2 Europe Nivolumab Sales by Application (2021-2032)
  8. 9.2.3 Europe Nivolumab Price by Application (2021-2032)
  9. 9.3 Europe Nivolumab Market Size by Country
  10. 9.3.1 Europe Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Nivolumab Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Nivolumab Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Nivolumab Market Size by Type
  2. 10.1.1 China Nivolumab Revenue by Type (2021-2032)
  3. 10.1.2 China Nivolumab Sales by Type (2021-2032)
  4. 10.1.3 China Nivolumab Price by Type (2021-2032)
  5. 10.2 China Nivolumab Market Size by Application
  6. 10.2.1 China Nivolumab Revenue by Application (2021-2032)
  7. 10.2.2 China Nivolumab Sales by Application (2021-2032)
  8. 10.2.3 China Nivolumab Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nivolumab Market Size by Type
  2. 11.1.1 Asia Nivolumab Revenue by Type (2021-2032)
  3. 11.1.2 Asia Nivolumab Sales by Type (2021-2032)
  4. 11.1.3 Asia Nivolumab Price by Type (2021-2032)
  5. 11.2 Asia Nivolumab Market Size by Application
  6. 11.2.1 Asia Nivolumab Revenue by Application (2021-2032)
  7. 11.2.2 Asia Nivolumab Sales by Application (2021-2032)
  8. 11.2.3 Asia Nivolumab Price by Application (2021-2032)
  9. 11.3 Asia Nivolumab Market Size by Country
  10. 11.3.1 Asia Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Nivolumab Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Nivolumab Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nivolumab Market Size by Type
  2. 12.1.1 SAMEA Nivolumab Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Nivolumab Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Nivolumab Price by Type (2021-2032)
  5. 12.2 SAMEA Nivolumab Market Size by Application
  6. 12.2.1 SAMEA Nivolumab Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Nivolumab Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Nivolumab Price by Application (2021-2032)
  9. 12.3 SAMEA Nivolumab Market Size by Country
  10. 12.3.1 SAMEA Nivolumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Nivolumab Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Nivolumab Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Nivolumab Value Chain Analysis
  2. 13.1.1 Nivolumab Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Nivolumab Production Mode & Process
  6. 13.2 Nivolumab Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Nivolumab Distributors
  9. 13.2.3 Nivolumab Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst